Difficulty: Medium
Average Score: 86%
Practice
A 17-year-old female with cystic fibrosis began taking a new medication to help loosen the mucus in her respiratory tract. The patient has not been adherent to her regimen of this drug, complaining that its smell makes her sick. Which is the most likely drug?
Correct answer
A
Rationale
The correct answer is A) Acetylcysteine. Acetylcysteine is a mucolytic agent commonly used to help loosen mucus in respiratory conditions like cystic fibrosis. It works by breaking down the disulfide bonds in mucus, making it less viscous and easier to clear from the airways. The patient's complaint of the drug's smell making her sick is characteristic of acetylcysteine, as it has a strong sulfur-like odor which can be unpleasant for some individuals.
Option B) Bromhexine is also a mucolytic agent, but it does not typically have a strong odor that would cause nausea or discomfort in patients.
Option C) Calfactant is a pulmonary surfactant replacement used in neonatal respiratory distress syndrome, not for loosening mucus in cystic fibrosis.
Option D) Dornase alfa is a recombinant human DNase enzyme used to break down DNA in mucus, not known for its smell causing adverse effects in patients.
Educationally, understanding the mechanisms of action, indications, and common side effects of mucolytic agents is crucial for healthcare providers to make informed decisions in treating patients with respiratory conditions like cystic fibrosis. Patient adherence and comfort with medications play a significant role in treatment outcomes, highlighting the importance of addressing concerns like drug smell in promoting treatment compliance.
Option B) Bromhexine is also a mucolytic agent, but it does not typically have a strong odor that would cause nausea or discomfort in patients.
Option C) Calfactant is a pulmonary surfactant replacement used in neonatal respiratory distress syndrome, not for loosening mucus in cystic fibrosis.
Option D) Dornase alfa is a recombinant human DNase enzyme used to break down DNA in mucus, not known for its smell causing adverse effects in patients.
Educationally, understanding the mechanisms of action, indications, and common side effects of mucolytic agents is crucial for healthcare providers to make informed decisions in treating patients with respiratory conditions like cystic fibrosis. Patient adherence and comfort with medications play a significant role in treatment outcomes, highlighting the importance of addressing concerns like drug smell in promoting treatment compliance.